9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

ConditionEpithelioid Mesothelioma|Pleural Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid MesotheliomaEstimated Enrollment: 116Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: TreatmentStudy ID Numbers: NCI-2011-02015|S0905|CDR0000665415|U10CA180888|U10CA032102Study First Received: February 5, 2010Last Updated: April 5, 2017Estimated Primary Completion Date: June 2017Primary Outcome Measures:Maximum tolerated dose determined if the dose-limiting toxicity rate is less than or equal to 33% according to NCI CTCAE version 4.0 (Phase I)|Progression-free survival (Phase II)|Overall survival (Phase II)|Response (Phase II)|Toxicity assessed using NCI CTCAE version 4.0 (Phase II)Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link:...

Continue reading

Nivolumab in Patients With Recurrent Malignant Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 33Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: N14MPNStudy First Received: July 6, 2015Last Updated: February 27, 2017Estimated Primary Completion Date: July 2017Primary Outcome Measures:DCR|PFS|OS|TTP|ORR|Safety and tolerability (The incidence of (serious) adverse events)Sponsors and Collaborators:The Netherlands Cancer Institute|Bristol-Myers SquibbResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02497508...

Continue reading

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

ConditionMesothelioma, MalignantEstimated Enrollment: 22Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: ONC-2014-002Study First Received: November 19, 2014Last Updated: February 9, 2017Estimated Primary Completion Date: December 2015Primary Outcome Measures:anti-tumor activity of Imatinib mesylate in combination with Gemcitabine|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of Response Evaluation Criteria In Solid Tumors (RECIST) criteria|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of overall survival (OS).|safety profile of the combination according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC)...

Continue reading

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

ConditionMesotheliomaEstimated Enrollment: 125Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: IFCT-1501Study First Received: March 9, 2016Last Updated: October 24, 2016Estimated Primary Completion Date: May 2017Primary Outcome Measures:Disease Control rate assessed by CT scan|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression-Free Survival|Overall Survival|Quality of Life|prognosis impact of blood biomarkers (exploratory studies)Sponsors and Collaborators:Intergroupe Francophone de Cancerologie ThoraciqueResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02716272...

Continue reading

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 390Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentStudy ID Numbers: NGR015|2009-016879-29Study First Received: March 17, 2010Last Updated: October 8, 2015Estimated Primary Completion Date: December 2016Primary Outcome Measures:Overall Survival (OS)|Progression-Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Disease Control|Safety and Toxicity according to NCI-CTCAE criteria (version 4.02)|Quality of life (QoL) according to Lung Cancer Symptom Scale|Evaluation of medical care utilization in the two treatment armsSponsors and Collaborators:MolMed S.p.A.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01098266...

Continue reading

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

ConditionMalignant Pleural Mesothelioma|Non-Small Cell Lung CancerEstimated Enrollment: 24Age Group: 20 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: D8807005Study First Received: January 21, 2015Last Updated: July 19, 2016Estimated Primary Completion Date: May 2017Primary Outcome Measures:Phase1: Assessment of safety of BBI608 given in combination with Pemetrexed and Cisplatin by reporting the adverse events and serious adverse events.|Phase1: Assessment of dose-limiting toxicities (DLTs).|Phase1: Pharmacokinetics profile of BBI608 when administered with pemetrexed and cisplatin.|Phase2: Progression Free Survival (PFS)|Phase1: Anti-tumor activity|Phase1: Progression Free Survival(PFS)|Phase1: Overall Survival(OS)|Phase2: Overall Survival (OS)|Phase2: Response...

Continue reading

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

ConditionMesotheliomaEstimated Enrollment: 248Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 15743|2012-003650-88Study First Received: November 9, 2015Last Updated: February 13, 2017Estimated Primary Completion Date: November 2017Primary Outcome Measures:Progression Free Survival|Overall survival (OS)|Patient-reported outcomes (PROs)|Objective response rate (ORR)|Duration of response (DOR)|Number of participants with treatment emergent adverse events as a measure of safety and tolerability|Number of participants with serious adverse events as a measure of safety and tolerability|Disease control rate (DCR)|Durable Response Rate (DRR)Sponsors and Collaborators:Bayer|ImmunoGen and MorphoSysResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02610140...

Continue reading

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

ConditionUnresectable Pleural or Peritoneal Malignant MesotheliomaEstimated Enrollment: 658Age Group: 18 Years to 99 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: TreatmentStudy ID Numbers: D4880C00003Study First Received: April 22, 2013Last Updated: January 24, 2017Estimated Primary Completion Date: January 2016Primary Outcome Measures:Overall survival (OS) time by treatment arm|Durable disease control rate by treatment arm|Length of progression-free survival by treatment arm|Overall response rate by treatment arm|Duration of response by treatment arm|Number of participants reporting any adverse event|Number of participants with changes in patient-reported outcomes|Number of participants reporting any serious...

Continue reading

Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 60Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: Master (No14)Study First Received: October 11, 2014Last Updated: June 8, 2016Estimated Primary Completion Date: June 2016Primary Outcome Measures:response rate|progression free survival (PFS)|overall survival (OS)|estimation of treatment related toxicitySponsors and Collaborators:Ain Shams UniversityResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02269878...

Continue reading

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

ConditionLung Cancer - Malignant Pleural MesotheliomaEstimated Enrollment: 27Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: UCL/12/0158|CMS # 1995|A15183|2012-001598-10|TBCStudy First Received: April 30, 2012Last Updated: October 26, 2016Estimated Primary Completion Date: September 2017Primary Outcome Measures:Maximum Tolerated Dose of Ganetespib|Progression Free SurvivalSponsors and Collaborators:University College, London|Cancer Research UKResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01590160...

Continue reading